Washington, May 17 (Prensa Latina) Heberprot-P, a drug developed by Cuba and currently the only one of its kind in the world to treat diabetic foot ulcers, could be in the US market by 2028, Dr. Lee Weingart, president of the US biotech company Discovery Therapeutics Caribe (DTC), based in Cleveland, Ohio, announced.